{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T18:20:32Z","timestamp":1794939632035,"version":"4.9.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008920","name":"University of Saskatchewan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008920","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Cannabis holds therapeutic potential; however, activation of the type 1 cannabinoid receptor (CB1R) via \u0394\n                      <jats:sup>9-<\/jats:sup>\n                      tetrahydrocannabinol (THC) is also responsible for the characteristic \u201chigh\u201d induced by cannabis. The pharmacology of the less abundant phytocannabinoid, cannabigerol (CBG), is poorly established, though it has been shown to exhibit promising therapeutic properties such as potential anxiolytic effects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We assessed the pharmacokinetics (PK) and pharmacodynamics (PD) of CBG in C57BL\/6Crl mice, hypothesizing that CBG would produce fewer PD effects than we had previously observed with THC, even when accounting for PK differences. Following oral (\n                      <jats:italic>p.o<\/jats:italic>\n                      .), intraperitoneal (\n                      <jats:italic>i.p<\/jats:italic>\n                      .), and intravenous (\n                      <jats:italic>i.v.<\/jats:italic>\n                      ) administration, the PK profile of CBG was assessed via blood sampling at specified time points (10 min, 30 min, 1 h, 3 h, 6 h, 12 h, 18 h, and 24 h). The blood concentrations of CBG were quantified by High-Performance Liquid Chromatography-Tandem Mass Spectrometry (HPLC-MS\/MS). A separate cohort of mice was treated with CBG and tested for cataleptic, hypothermic, anti-nociceptive, and locomotor effects to correlate the PK profile of CBG with CBG\u2019s observed PD effects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results and Discussion<\/jats:title>\n                    <jats:p>Our data reveal that CBG was not intoxicating, even when accounting for the route of administration and blood concentration. Our findings support previous reports that CBG is not intoxicating and reveal that even if CBG were present at sufficiently high concentrations in cannabis products, it would not produce intoxicating effects like those of THC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1672098","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T06:29:48Z","timestamp":1765261788000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Pharmacokinetics and pharmacodynamics of cannabigerol (CBG) in the C57BL\/6Crl mouse"],"prefix":"10.3389","volume":"16","author":[{"given":"Ayat","family":"Zagzoog","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenzie","family":"Halter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nini","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alayna M.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Andres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Alcorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Laprairie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"B2","doi-asserted-by":"publisher","first-page":"908198","DOI":"10.3389\/fphar.2022.908198","article-title":"Medical cannabis activity against inflammation: active compounds and modes of action","volume":"13","author":"Anil","year":"2022","journal-title":"Front. Pharmacology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.bcp.2013.01.017","article-title":"Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease","volume":"85","author":"Borrelli","year":"2013","journal-title":"Biochem. Pharmacology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3336516","DOI":"10.1155\/2022\/3336516","article-title":"Pharmacological aspects and biological effects of cannabigerol and its synthetic derivatives","volume":"2022","author":"Calapai","year":"2022","journal-title":"Evidence\u2010Based Complementary Altern. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1476-5381.2009.00515.x","article-title":"Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist","volume":"159","author":"Cascio","year":"2010","journal-title":"Br. Journal Pharmacology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.lfs.2012.06.009","article-title":"Sex differences in cannabinoid pharmacology: a reflection of differences in the endocannabinoid system?","author":"Craft","year":"2013","journal-title":"Life Sciences"},{"key":"B7","doi-asserted-by":"publisher","first-page":"16163","DOI":"10.1038\/s41598-024-66879-0","article-title":"Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial","volume":"14","author":"Cuttler","year":"2024","journal-title":"Sci. Rep."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1124\/jpet.107.134809","article-title":"Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8","volume":"325","author":"De Petrocellis","year":"2008","journal-title":"J. Pharmacology Experimental Therapeutics"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1111\/j.1476-5381.2010.01166.x","article-title":"Effects of cannabinoids and cannabinoid\u2010enriched cannabis extracts on TRP channels and endocannabinoid metabolic enzymes","volume":"163","author":"De Petrocellis","year":"2011","journal-title":"Br. Journal Pharmacology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s00213-011-2415-0","article-title":"Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), \u0394\u2079-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour","volume":"219","author":"Deiana","year":"2012","journal-title":"Psychopharmacology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.pbb.2010.03.004","article-title":"Antidepressant-like effect of \u03949-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L","author":"El-Alfy","year":"2010","journal-title":"Pharmacol. Biochem. Behavior"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1007\/s11481-012-9399-3","article-title":"A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis","volume":"7","author":"Granja","year":"2012","journal-title":"J. Neuroimmune Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1124\/jpet.117.240192","article-title":"Apparent CB1 receptor rimonabant affinity estimates: combination with THC and synthetic cannabinoids in the mouse in vivo triad model","volume":"362","author":"Grim","year":"2017","journal-title":"J. Pharmacol. Exp. Therapeutics"},{"key":"B14","doi-asserted-by":"publisher","first-page":"7929","DOI":"10.3390\/ijms23147929","article-title":"The origin and biomedical relevance of cannabigerol","volume":"23","author":"Jastrz\u0105b","year":"2022","journal-title":"Int. Journal Molecular Sciences"},{"key":"B15","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1089\/can.2023.0083","article-title":"Evaluating potential anxiolytic effects of minor cannabinoids and terpenes after acute and chronic oral administration in rats","volume":"8","author":"Jenkins","year":"2023","journal-title":"Cannabis Cannabinoid Research"},{"key":"B16","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2133\/dmpk.dmpk-12-rg-129","article-title":"Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19","volume":"28","author":"Jiang","year":"2013","journal-title":"Drug Metabolism Pharmacokinetics"},{"key":"B17","doi-asserted-by":"publisher","first-page":"855","DOI":"10.3390\/ijms24010855","article-title":"Anti-inflammatory effects of cannabigerol in rheumatoid arthritis synovial fibroblasts and peripheral blood mononuclear cell cultures are partly mediated by TRPA1","volume":"24","author":"Lowin","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1124\/pharmrev.122.000600","article-title":"Goods and bads of the endocannabinoid system as a therapeutic target: lessons learned after 30 years","volume":"75","author":"Maccarrone","year":"2023","journal-title":"Pharmacol. Reviews"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1183019","DOI":"10.3389\/fphar.2023.1183019","article-title":"Cannabigerol modulates \u03b12-adrenoceptor and 5-HT1A receptor-mediated electrophysiological effects on dorsal raphe nucleus and locus coeruleus neurons and anxiety behavior in rat","volume":"14","author":"Mendiguren","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/cpns.31","article-title":"Cannabinoid\u2010induced tetrad in mice","volume":"80","author":"Metna\u2010Laurent","year":"2017","journal-title":"Curr. Protocols Neuroscience"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3389\/fphar.2018.01365","article-title":"A systematic review on the pharmacokinetics of cannabidiol in humans","volume":"9","author":"Millar","year":"2018","journal-title":"Front. Pharmacology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1124\/jpet.120.000340","article-title":"The pharmacological case for cannabigerol","volume":"376","author":"Nachnani","year":"2021","journal-title":"J. Pharmacology Experimental Therapeutics"},{"key":"B23","doi-asserted-by":"publisher","first-page":"632","DOI":"10.3389\/fphar.2018.00632","article-title":"Cannabigerol action at cannabinoid CB1 and CB2 receptors and at CB1\u2013CB2 heteroreceptor complexes","volume":"9","author":"Navarro","year":"2018","journal-title":"Front. Pharmacology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1373\/clinchem.2016.263475","article-title":"Free and glucuronide whole blood cannabinoids' pharmacokinetics after controlled smoked, vaporized, and oral cannabis administration in frequent and occasional cannabis users: identification of recent cannabis intake","volume":"62","author":"Newmeyer","year":"2016","journal-title":"Clin. Chemistry"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1371\/journal.pbio.3000410","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research","volume":"40","author":"Hurst","year":"2020","journal-title":"J. Cereb. Blood Flow Metabolism"},{"key":"B26","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00213-010-2157-4","article-title":"Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews","volume":"215","author":"Rock","year":"2011","journal-title":"Psychopharmacology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1021\/acs.biochem.2c00383","article-title":"Metabolites of cannabigerol generated by human cytochrome P450s are bioactive","volume":"61","author":"Roy","year":"2022","journal-title":"Biochemistry"},{"key":"B28","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1089\/can.2021.0058","article-title":"Survey of patients employing cannabigerol-predominant cannabis preparations: perceived medical effects, adverse events, and withdrawal symptoms","volume":"7","author":"Russo","year":"2022","journal-title":"Cannabis Cannabinoid Research"},{"key":"B29","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1124\/jpet.124.002212","article-title":"Select minor cannabinoids from Cannabis sativa are cannabimimetic and antinociceptive in a mouse model of chronic neuropathic pain","volume":"391","author":"Schwarz","year":"2024","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B30","volume-title":"Bioanalytical Method Validation Guidance for Industry","year":"2018"},{"key":"B31","doi-asserted-by":"publisher","first-page":"20405","DOI":"10.1038\/s41598-020-77175-y","article-title":"In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa","volume":"10","author":"Zagzoog","year":"2020","journal-title":"Sci. Rep."},{"key":"B32","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1124\/jpet.123.001998","article-title":"The intoxication equivalency of 11-Hydroxy-\u03949-Tetrahydrocannabinol relative to \u03949-Tetrahydrocannabinol","volume":"391","author":"Zagzoog","year":"2024","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1672098\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T06:29:49Z","timestamp":1765261789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1672098\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":31,"alternative-id":["10.3389\/fphar.2025.1672098"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1672098","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fphar.2025.1672098.s001","asserted-by":"subject"}]},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"article-number":"1672098"}}